Discover open access scientific publications

Search, annotate, share and cite publications

Publications by L. Fedorova

Retreatment With Nivolumab in Patients With R/R Classical Hodgkin Lymphoma After Discontinuation of the Therapy With Immune Checkpoint Inhibitors

Hematological Oncology

English

Coincidence of Synteny Breakpoints With Malignancy-Related Deletions on Human Chromosome 3

Proceedings of the National Academy of Sciences of the United States of America

Multidisciplinary

2003

English

Related publications

Combination of Nivolumab and Bendamustine in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Hematological Oncology

English

Retreatment With Immune Checkpoint Inhibitors in Solid Tumors: A Systematic Review

2020

English

A First-In-Human Trial of the Novel Multi-Action Therapy Tinostamustine (Edo-S101) in Patients With Relapsed/Refractory (R/R) Hodgkin Lymphoma (Hl)

Hematological Oncology

English

Concurrent Therapy With Immune Checkpoint Inhibitors and TNFα Blockade in Patients With Gastrointestinal Immune-Related Adverse Events

Journal for ImmunoTherapy of Cancer

English

A Phase 1/2 Study of Brentuximab Vedotin in Pediatric Patients With Relapsed/Refractory (R/R) Systemic Anaplastic Large-Cell Lymphoma (Salcl) or R/R Hodgkin Lymphoma (Hl)

Hematological Oncology

English

Immune Checkpoint Inhibition in Classical Hodgkin Lymphoma: From Early Achievements Towards New Perspectives

Journal of Oncology

Oncology

2019

English

Recurrent Pneumonitis in Patients With Melanoma Treated With Immune Checkpoint Inhibitors

English

Response-Adapted Treatment With Nivolumab and Brentuximab Vedotin in Young Patients With Relapsed/Refractory Classical Hodgkin Lymphoma: Checkmate 744 Subgroup Analyses

Hematological Oncology

English

REAL-WORLD HEALTHCARE RESOURCE UTILIZATION (HRU) OF CLASSICAL HODGKIN LYMPHOMA (cHL) PATIENTS (PTS) TREATED WITH ANTI-PD1 CHECKPOINT INHIBITORS IN THE UNITED STATES (US)

Hematological Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by L. Fedorova

Retreatment With Nivolumab in Patients With R/R Classical Hodgkin Lymphoma After Discontinuation of the Therapy With Immune Checkpoint Inhibitors

Coincidence of Synteny Breakpoints With Malignancy-Related Deletions on Human Chromosome 3

Related publications

Combination of Nivolumab and Bendamustine in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Retreatment With Immune Checkpoint Inhibitors in Solid Tumors: A Systematic Review

A First-In-Human Trial of the Novel Multi-Action Therapy Tinostamustine (Edo-S101) in Patients With Relapsed/Refractory (R/R) Hodgkin Lymphoma (Hl)

Concurrent Therapy With Immune Checkpoint Inhibitors and TNFα Blockade in Patients With Gastrointestinal Immune-Related Adverse Events

A Phase 1/2 Study of Brentuximab Vedotin in Pediatric Patients With Relapsed/Refractory (R/R) Systemic Anaplastic Large-Cell Lymphoma (Salcl) or R/R Hodgkin Lymphoma (Hl)

Immune Checkpoint Inhibition in Classical Hodgkin Lymphoma: From Early Achievements Towards New Perspectives

Recurrent Pneumonitis in Patients With Melanoma Treated With Immune Checkpoint Inhibitors

Response-Adapted Treatment With Nivolumab and Brentuximab Vedotin in Young Patients With Relapsed/Refractory Classical Hodgkin Lymphoma: Checkmate 744 Subgroup Analyses

REAL-WORLD HEALTHCARE RESOURCE UTILIZATION (HRU) OF CLASSICAL HODGKIN LYMPHOMA (cHL) PATIENTS (PTS) TREATED WITH ANTI-PD1 CHECKPOINT INHIBITORS IN THE UNITED STATES (US)